Aurobindo Pharma Limited, which has suffered a setback in exports to USA after USFDA's import ban alert on products manufactured at Cephalosporin facility of APL at Chitkul village near here, said they may incur a revenue loss to the extent of $2 million per month till the issue remains unresolved.
The Economic Times